| Title |
Cost Utility of Telaprevir–PR (Peginterferon–Ribavirin) Versus Boceprevir–PR and Versus PR Alone in Chronic Hepatitis C in The Netherlands
|
|---|---|
| Published in |
Applied Health Economics and Health Policy, August 2014
|
| DOI | 10.1007/s40258-014-0120-y |
| Pubmed ID | |
| Authors |
Aikaterini Vellopoulou, Michel van Agthoven, Annemarie van der Kolk, Robert J. de Knegt, Gilles Berdeaux, Sandrine Cure, Florence Bianic, Mark Lamotte |
| Abstract |
The hepatitis C virus may lead to cirrhosis, liver cancer, liver transplant, and increased mortality. With standard treatment peginterferon-alpha and ribavirin (PR), sustained viral response (SVR) was less than 50 %. SVR rates improve greatly when PR is combined with telaprevir or boceprevir. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 33 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | 3% |
| Unknown | 32 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 30% |
| Student > Bachelor | 4 | 12% |
| Student > Master | 4 | 12% |
| Student > Ph. D. Student | 3 | 9% |
| Other | 2 | 6% |
| Other | 4 | 12% |
| Unknown | 6 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 55% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Economics, Econometrics and Finance | 2 | 6% |
| Agricultural and Biological Sciences | 1 | 3% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Other | 2 | 6% |
| Unknown | 7 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 August 2014.
All research outputs
#20,233,547
of 22,759,618 outputs
Outputs from Applied Health Economics and Health Policy
#719
of 771 outputs
Outputs of similar age
#193,891
of 230,503 outputs
Outputs of similar age from Applied Health Economics and Health Policy
#19
of 24 outputs
Altmetric has tracked 22,759,618 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 771 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 230,503 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.